Comparing the outcomes of statins and PCSK9 inhibitors in LDL management in patients with heterozygous familial hypercholesterolemia (HeFH) and diabetes
DOI:
https://doi.org/10.62497/IRABCS.2024.39Keywords:
heterozygous familial hypercholesterolemia, diabetes mellitus, statins, PCSK9 inhibitors, LDL-C reduction, cardiovascular outcome, patient satisfactionAbstract
Background: Aggressive lipid-lowering methods are required for cardiovascular risk management when heterozygous familial hypercholesterolemia (HeFH) is combined with diabetes mellitus. Though statins have been the mainstay of treatment, a viable substitute is the development of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors. Comparative information about their safety and effectiveness in this population is still lacking, though.
Aim: This study aims to systematically compare the outcomes of statins and PCSK9 inhibitors in LDL management for patients with HeFH and diabetes.
Methodology: A retrospective cohort study was conducted at Hayabad Medical Complex, encompassing 62 individuals with HeFH and diabetes mellitus. Data on demographic characteristics, treatment regimens, LDL-C reduction efficacy, cardiovascular outcomes, safety profile, and patient adherence were analyzed.
Results: PCSK9 inhibitors demonstrated superior efficacy in reducing LDL-C levels compared to statins, achieving a mean reduction of 70.9% versus 55.8%, respectively. Moreover, individuals receiving PCSK9 inhibitors experienced a significantly lower incidence of cardiovascular events (2 events vs. 6 events) and reported higher levels of patient satisfaction. Both therapies exhibited a favorable safety profile.
Conclusion: Our findings underscore the potential of PCSK9 inhibitors as a preferred therapeutic option over statins in patients with HeFH and diabetes, offering superior LDL-C reduction efficacy, cardiovascular risk reduction, and patient satisfaction. These results highlight the importance of personalized treatment approaches in optimizing cardiovascular risk management.
Keywords: heterozygous Familial Hypercholesterolemia, diabetes mellitus, statins, PCSK9 inhibitors, LDL-C reduction, cardiovascular outcomes, patient satisfaction
Downloads
References
Arca M. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors. Atherosclerosis. 2017 Jan 1;256:134-45.
Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JH, de Graaf J, Visseren FL, Imholz BP, van Lennep JE, Huijgen R, Kastelein JJ. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Journal of clinical lipidology. 2018 Jul 1;12(4):972-80.
Climent E, Pérez-Calahorra S, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Sánchez-Hernández RM, Valdivielso P, Ascaso JF, Pedro-Botet J. Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes. Revista Española de Cardiología (English Edition). 2020 Sep 1;73(9):718-24.
Climent E, Pérez-Calahorra S, Marco-Benedí V, Plana N, Sánchez R, Ros E, Ascaso JF, Puzo J, Almagro F, Lahoz C, Civeira F. Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. Scientific reports. 2017 Jul 17;7(1):5596.
Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D'Erasmo L, Averna M, Zambon A, Catapano AL, Russo P. Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. Journal of the American Heart Association. 2023 Nov 7;12(21):e026550.
Vuorio A, Watts GF, Kovanen PT. Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?. European Heart Journal. 2016 May 1;37(17):1353-6.
Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 Oct 1;277:483-92.
Catapano AL, Pirillo A, Norata GD. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vascular health and risk management. 2017 Sep 4:343-51.
McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. Journal of the American Heart Association. 2019 Dec 17;8(24):e013225.
Liu MM, Peng J, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong Q, Li JJ. Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology. 2021 Dec 1;28(16):1807-16.
Miname MH, Santos RD. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Progress in cardiovascular diseases. 2019 Sep 1;62(5):414-22.
van Delden XM, Huijgen R, Wolmarans KH, Brice BC, Barron JK, Blom DJ, Marais AD. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: minority at target despite large reductions in LDL-C. Atherosclerosis. 2018 Oct 1;277:327-33.
Tomlinson B, Patil NG, Fok M, Lam CW. Role of PCSK9 inhibitors in patients with familial hypercholesterolemia. Endocrinology and Metabolism. 2021 Apr;36(2):279.’
Papademetriou V, Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Dimitriadis K, Tsioufis K. Role of PCSK9 inhibitors in high risk patients with dyslipidemia: focus on familial hypercholesterolemia. Current pharmaceutical design. 2018 Sep 1;24(31):3647-53.
Hovingh GK, Goldberg AC, Moriarty PM. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit. Journal of clinical lipidology. 2017 May 1;11(3):602-16.
Masana L, Plana N, Pérez-Calahorra S, Ibarretxe D, Lamiquiz-Moneo I, Pedro-Botet J, Suárez-Tembra M, Valdivielso P, Ortega E, Civeira F. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. Atherosclerosis. 2017 Jul 1;262:107-12.
Lui DT, Lee AC, Tan KC. Management of familial hypercholesterolemia: current status and future perspectives. Journal of the Endocrine Society. 2021 Jan;5(1):bvaa122.
Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovascular Drugs and Therapy. 2016 Oct;30:473-83.
Mohd Kasim NA, An CY, Nawawi H. Familial hypercholesterolaemia: An updated overall management. Journal of Clinical and Heatlh Sciences. 2020 Nov 1;5(2):19-38.
D'Erasmo L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study. Nutrition, Metabolism and Cardiovascular Diseases. 2020 Oct 30;30(11):2027-35.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Asif shah, Mahnoor Bashir, Rawish Gul, Alina murad, Brikhna Khttak (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright to their work published in the IRABCS journal under the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY-NC-ND 4.0).
![](<img src="https://assets.crossref.org/logo/crossref-logo-landscape-200.svg" width="200" height="68" alt="Crossref logo">){kind=logo}
